Gilead scores PrEP approval for Descovy — kicking off marketing push before Truvada generics swarm
The FDA has cleared Gilead’s Descovy — a top pipeline drug it spent a priority review voucher on — for HIV pre-exposure prophylaxis in a broad, but …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
